TABLE 2.
Characteristics at the time of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) prescription a
Overall (n = 54) | After the first year of T2D diagnosis (n = 26) | Within the first year of T2D diagnosis (n = 28) | Estimated contrast between prescribing groups b (95% CI) | |
---|---|---|---|---|
Age (y) | 14.8 (1.9) | 15.2 (1.9) | 14.5 (1.9) | −0.69 (−1.73, 0.35) |
BMI (kg/m2) | 37.9 (7.7) | 37.5 (6.3) | 38.3 (8.8) | 0.79 (−3.43, 5.01) |
BMI percentage of the 95th percentile | 137 (26.9) | 134 (24.4) | 140 (29.3) | 5.68 (−9.11, 20.47) |
HbA1c (%) | 9.4 (2.8) | 10.4 (2.8) | 8.5 (2.4) | −1.83 (−3.28, −0.39)* |
Male sex (%) | 26 (48.1) | 11 (42.3) | 15 (53.6) | 1.57 (0.54, 4.61) |
Race/ethnicity (%) | ||||
African American/Black | 17 (31.5) | 10 (38.5) | 7 (25.0) | Reference |
White, non‐Hispanic | 10 (18.5) | 4 (15.4) | 6 (21.4) | 2.14 (0.44, 10.53) |
White, Hispanic | 9 (16.7) | 4 (15.4) | 5 (17.9) | 1.79 (0.35, 9.13) |
Asian | 6 (11.1) | 4 (15.4) | 2 (7.1) | 0.71 (0.10, 5.04) |
Multiple | 4 (7.4) | 1 (3.8) | 3 (10.7) | 4.29 (0.37, 50.21) |
Native American | 3 (3.0) | 2 (2.8) | 1 (3.6) | 1.79 (0.14, 22.70) |
Missing | 6 (11.1) | 2 (7.7) | 4 (14.3) | |
Concomitant insulin (%) | 36 (66.7) | 21 (80.8) | 15 (53.6) | 0.27 (0.08, 094)* |
Long‐acting insulin dose (units/kg/d) | 0.42 (0.32) | 0.5 (0.38) | 0.32 (0.15) | −0.18 (−0.39, 0.03) |
Concomitant weight‐loss medications (%) | ||||
Stimulants | 9 (16.7) | 5 (19.2) | 4 (14.3) | 0.73 (0.17, 3.09) |
Topiramate | 8 (14.8) | 3 (11.5) | 5 (17.9) | 1.67 (0.36, 7.80) |
Bupropion | 5 (9.3) | 3 (11.5) | 2 (7.1) | 0.59 (0.09, 3.85) |
Naltrexone | 2 (3.7) | 0 (0.0) | 2 (7.1) | N/A |
Concomitant diabetes medications (%) | ||||
Metformin | 45 (83.3) | 22 (84.6) | 23 (82.1) | 0.84 (0.20, 3.53) |
DPP‐IV inhibitors | 4 (7.4) | 1 (3.8) | 3 (10.7) | 3.00 (0.29, 30.84) |
SGLT‐2 inhibitors | 10 (18.5) | 2 (7.7) | 8 (28.6) | 4.80 (0.91, 25.23) |
Sulphonylureas | 3 (5.6) | 1 (3.8) | 2 (7.1) | 1.92 (0.16, 22.56) |
Abbreviations: BMI, body mass index; DPP‐IV, dipeptidyl peptidase‐IV; SGLT‐2, sodium‐glucose co‐transporter‐2; T2D, type 2 diabetes.
Continuous variables are described as value (SD). Categorical variables are described as n (%).
Estimates are mean differences or odds ratios.
P < .05.